Diagnosis and treatment of transthyretin amyloidosis cardiomyopathy: A position statement of the Polish Cardiac Society

J Grzybowski, P Podolec, K Holcman… - Polish Heart …, 2023 - journals.viamedica.pl
Considering the rare incidence of transthyretin amyloidosis cardiomyopathy (ATTR-CM) in
Poland, patients encounter difficulties at the stages of diagnosis and treatment. For …

Sex-related differences in clinical presentation and all-cause mortality in patients with cardiac transthyretin amyloidosis and light chain amyloidosis

M Zampieri, A Argiro, M Allinovi, L Tassetti… - International Journal of …, 2022 - Elsevier
We aimed to ascertain whether sex-related differences are relevant to clinical presentation,
cardiac phenotype and all-cause mortality in different types of cardiac amyloidosis, a field …

Phenotype and clinical outcomes of Glu89Lys hereditary transthyretin amyloidosis: a new endemic variant in Spain

F De Frutos, JP Ochoa, C Gómez-González… - Amyloid, 2023 - Taylor & Francis
Abstract Background The p. Glu109Lys variant (Glu89Lys) is a rare cause of hereditary
transthyretin amyloidosis (ATTRv) for which clinical spectrum remains unresolved. We …

Transthyretin amyloid cardiomyopathy in patients with unexplained increased left ventricular wall thickness

K Holcman, M Kostkiewicz, W Szot, B Ćmiel… - … International Journal of …, 2024 - Springer
Amyloid cardiomyopathy (CA) was previously considered a rare disease; however, rapid
advancements in imaging modalities have led to an increased frequency of its diagnosis …

Biochemical and biophysical properties of a rare TTRA81V mutation causing mild transthyretin amyloid cardiomyopathy

Q Sha, Y Zhang, M Wang, J Sun, Y Zhang… - ESC Heart …, 2024 - Wiley Online Library
Aims We conducted a presentation on an 84‐year‐old male patient who has been
diagnosed with TTRA81V (p. TTRA101V) hereditary transthyretin cardiac amyloidosis …

Rare c.302C>T TTR Variant Associated with Transthyretin Amyloidosis

D Žebrauskienė, E Sadauskienė, R Masiulienė… - Medicina, 2024 - mdpi.com
Background and Objectives: Hereditary transthyretin amyloidosis (ATTRv) is a rare disease
caused by pathogenic variants in the transthyretin (TTR) gene. More than 140 different …

The scintigraphic diagnosis of cardiac amyloidosis. An expert opinion endorsed by the Section of Nuclear Medicine of the Polish Cardiac Society and the Polish …

K Holcman, M Dziuk, J Grzybowski… - Nuclear Medicine …, 2022 - journals.viamedica.pl
Amyloid transthyretin cardiomyopathy is a progressive disease that confers significant
mortality. While it is relatively rare, the frequency of diagnoses has risen with the increased …

[PDF][PDF] Amino acid extravasation: a rare red flag to keep in mind during peptide receptor radioligand therapy (PRRT) with [177Lu] Lu-DOTATATE

G Divband, SH Alavi, Z Adinehpour… - Nucl. Med. Rev …, 2022 - journals.viamedica.pl
A 64 years-old woman with intestinal neuroendocrine tumor (NET) and multiple liver
metastases was referred for peptide receptor radioligand therapy (PRRT) with [177Lu] Lu …

Stanowisko ekspertów Polskiego Towarzystwa Kardiologicznego dotyczące diagnostyki i leczenia amyloidozy transtyretynowej serca

J Grzybowski, P Podolec, K Holcman… - Polish Heart …, 2023 - journals.viamedica.pl
Z uwagi na rzadkie występowanie w Polsce amyloidozy transtyretynowej serca (ATTR-CM,
transthyretin amyloidosis cardiomyopathy) pacjenci napotykają na liczne trudności na etapie …

Hereditary Transthyretin Amyloidosis: Opportunities & Challenges

SG Smith - 2021 - search.proquest.com
Hereditary transthyretin amyloidosis (hATTR) is a progressive, autosomal dominant,
multisystem disease with incomplete and age-related penetrance. The disease presents …